Navigation Links
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
Date:6/5/2008

dications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its program for MPS IVA, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials related to the enzyme replacement therapy for MPS IVA; the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory agencies, particularly with respect to the enzyme replacement therapy for MPS IVA, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10- K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzy
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Host Research and Development Day June 5th
2. BioMarin to Present at the Bank of America Healthcare Conference
3. BioMarin Announces First Quarter 2008 Financial Results
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 Alternative Fuels Americas, Inc. (AFAI) announced today ... Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... The SPV shall be called AFAI Jatro Green Ethiopia and ... shareholder. The SPV shall pursue Jatropha planting and biofuels production ... Ethiopia . "Although we have experienced ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
(Date:9/17/2014)... Escape Alert, LLC . filed international patents ... alert owners if their pet has escaped and enable them to ... in the pet’s body. This is the first implantable microchip ... been around for many years, they are passive until read by ... a pet’s location or alert the owner that the pet has ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... Improve Diabetes Care, PERRYSBURG, Ohio, Feb. 25 ... medical, humanistic and financial elements of,diabetes care will ... (NBCH). FrontPath Health Coalition, through its non-profit Western,Lake ... lead this,community-wide effort that includes the City of ...
... NEW YORK, Feb. 25 Care to Care, a ... has signed,Touchstone Health HMO Inc. as a client. As ... portfolio has grown to over 700,000,lives., (Logo: ... and flattered to be selected as the Radiology,Benefit Manager ...
... One-year Agreement With Guaranteed Purchase Minimums - Carrington Provides ... ... Distribution, IRVING, Texas, Feb. 25 ... has signed,a supply agreement with Universal Harvest Corporation of Nevada. ...
Cached Biology Technology:FrontPath Health Coalition To Lead Community-wide Group in Pilot Program 2FrontPath Health Coalition To Lead Community-wide Group in Pilot Program 3Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health 2Carrington and Universal Harvest Sign Supply Agreement 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... its own bacterial identity. That,s the conclusion of University ... studied the genetic fingerprints of bacteria on 57 species ... study demonstrates for the first time that host plants ... possess very different microbial communities on their leaves," said ... in the UO,s Institute of Ecology and Evolution who ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2
... Joslin scientists report the first generation of human induced pluripotent ... maturity onset diabetes of the young (MODY). These cells offer ... in the development of MODY and testing potential treatments. The ... Human induced pluripotent stem cells (hiPSCs) are adult cells ...
... 2013 -- Deborah E. Wiley, Chair of The Wiley ... JWb), announced today that the twelfth annual Wiley Prize ... Young, Rockefeller University, Dr. Jeffrey Hall, Brandeis University (Emeritus), ... Prize is being awarded to Dr. Young, Dr. Hall ...
... Researchers from the group on stem cells and cancer at ... of the gene regulation circuits which would make it possible ... This finding is essential to generate these cells in a ... with leukaemia or other diseases who need a transplant and ...
Cached Biology News:Joslin scientists find first human iPSC from patients with maturity onset diabetes of the young 212th annual Wiley Prize in Biomedical Sciences awarded 212th annual Wiley Prize in Biomedical Sciences awarded 31 of the key circuits in regulating genes involved in producing blood stem cells is deciphered 2
Please email us with project details and we will respond within 24 hours to your query!...
Loading Buffer...
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Biology Products: